Publication

Interleukin 2 immune response generating formulation, used for treating cancer, comprises IL 2 coupled to transport protein, monoclonal anti IL 2 antibody or monoclonal anti CD 25 antibody

2006
Patents

Abstract

NOVELTY - A formulation comprising one or more components chosen from interleukin (IL)-2 or a derivative thereof coupled to a transport protein, a monoclonal anti-IL-2 antibody, a cancer vaccine based on specific antigens of tumors or tumor growth factors or a monoclonal anti-CD25 antibody, is new. USE - The formulations are used to produce drugs for inducing an anti-IL-2 immune response capable of inhibiting the growth of tumors in cancer patients (claimed). ADVANTAGE - Auto-antibodies which block binding of IL-2 to its receptor are induced and inhibit tumor growth. DETAILED DESCRIPTION - A therapeutic formulation capable of generating an immune response to Interleukin 2 (IL-2), used for treating cancer patients, comprises at least one component chosen from: (a) IL-2 or a derivative thereof coupled to a transport protein genetically or by chemical bonding, as well as a suitable adjuvant; (b) a monoclonal anti-IL-2 antibody; (c) a cancer vaccine based on specific antigens of tumors or tumor growth factors; or (d) a monoclonal anti-CD25 antibody.

Official source

https://infoscience.epfl.ch/entities/publication/3595469d-fcce-42d7-a527-21835bbab500

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

2006
Patents

Abstract

Official source

https://infoscience.epfl.ch/entities/publication/3595469d-fcce-42d7-a527-21835bbab500

About this result

Related concepts (32)

Treatment of cancer

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality, most commonly as a series of separate treatments (e.g. chemotherapy before surgery). The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of the patient (performance status). Cancer genome sequencing helps in determining which cancer the patient exactly has for determining the best therapy for the cancer.

Cancer

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths.

Monoclonal antibody therapy

Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient's immune system to attack those cells. Alternatively, in radioimmunotherapy a radioactive dose localizes a target cell line, delivering lethal chemical doses. Antibodies are used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses.

Related publications (32)

Interleukin 2 immune response generating formulation, used for treating cancer, comprises IL 2 coupled to transport protein, monoclonal anti IL 2 antibody or monoclonal anti CD 25 antibody

Chat with Graph Search

A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress–Induced Inflammation

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

6-diazo-5-oxo-l-norleucine prodrugs